• Z-IETD-FMK in Apoptosis Research: Beyond Caspase-8 Inhibitio

  2026-08-04

  Explore the advanced utility of Z-IETD-FMK, a potent caspase-8 inhibitor, in dissecting apoptosis and immune cell activation. This article delves into unique experimental strategies and recent insights, setting it apart as an essential guide for researchers in cell death and immune modulation.

• Targeting DHHC9-Mediated STRN4 Palmitoylation in Cancer Meta

  2026-08-03

  This study identifies DHHC9-mediated palmitoylation of STRN4 as a critical driver of YAP-dependent cancer metastasis. Pharmacological inhibition of DHHC9 suppresses tumor cell migration by disrupting the Hippo pathway, offering a novel therapeutic target for adenocarcinoma intervention.

• Structure-Based Discovery of Natural Inhibitors for SARS-CoV

  2026-08-03

  This article analyzes a structure-based virtual screening study that identified thymopentin and oleuropein as potent natural product inhibitors of the SARS-CoV-2 NSP15 endoribonuclease. The findings highlight the potential of computational drug discovery for targeting viral immune evasion and inform future antiviral strategies.

• Evaluating Commercial Protease Inhibitor Libraries for COVID

  2026-08-02

  This review critically assesses commercial protease inhibitor and protein–protein interaction inhibitor libraries as resources for virtual screening in COVID-19 drug design. The paper highlights gaps in the documentation of compound selection, design rationale, and validation, underscoring the need for higher transparency and more robust library curation in early-stage drug discovery.

• CX-5461: RNA Polymerase I Inhibitor Workflows in Cancer Rese

  2026-08-01

  CX-5461 is a potent RNA polymerase I inhibitor that enables targeted inhibition of ribosome biogenesis, supporting advanced cancer research workflows and combinatorial therapy strategies. This article delivers practical protocols, troubleshooting guidance, and key innovations for using APExBIO’s CX-5461 in both solid tumor models and studies of chemoresistance.

• Z-LEHD-FMK in Translational Apoptosis: Precision Tools for C

  2026-07-31

  Explore how Z-LEHD-FMK, a selective irreversible caspase-9 inhibitor, advances apoptosis research beyond standard assays—revealing new strategies for cell death detection, neuroprotection, and cardioprotection. This article uniquely bridges mechanism, protocol, and translational insight.

• MK-5108 (VX-689): Translational Aurora A Inhibition Beyond R

  2026-07-31

  Explore how MK-5108 (VX-689) redefines selective Aurora A kinase inhibition, with unique insight into its mechanism, assay protocol optimization, and practical implications for tumor cell proliferation studies. Discover an advanced, evidence-driven resource for cancer research.

• MK-5108 (VX-689): Precision Aurora A Inhibition in High-Risk

  2026-07-30

  Explore how MK-5108 (VX-689), a highly selective Aurora A kinase inhibitor, advances cancer research by enabling precise cell cycle arrest and tumor suppression assays. This in-depth analysis reveals unique insights from recent retinoblastoma studies and practical guidance for advanced oncology workflows.

• 2-Hydroxypropyl-β-cyclodextrin: Solubility Workflows & QC Gu

  2026-07-30

  2-Hydroxypropyl-β-cyclodextrin addresses the challenge of solubilizing poorly water-soluble, hydrophobic compounds—especially those with aromatic or phenyl groups—by forming aqueous inclusion complexes. Its validated use is in pharmaceutical and biochemical research as a drug formulation excipient or solubility enhancer. Applications outside these contexts lack documented support and are not recommended.

• GluN2A/B Regulation of Gap Junctions in TMJ Inflammatory All

  2026-07-29

  This study demonstrates that NMDA receptor subunits GluN2A and GluN2B mediate the expression of connexins and pannexins in trigeminal ganglia, contributing to orofacial pain during TMJ inflammation. By detailing distinct signaling pathways and glial cell interactions, the work identifies novel targets for therapeutic intervention in inflammatory allodynia.

• Tropifexor (LJN452): Precision FXR Modulation in Barrier Res

  2026-07-29

  Tropifexor (LJN452) empowers researchers to dissect FXR-driven metabolic and intestinal barrier pathways with sub-nanomolar potency. This guide translates recent advances in triacetin metabolism and epithelial defense into actionable experimental workflows, troubleshooting, and comparative insights.

• RNAi Screening Uncovers Vesicular Transport in SARS-CoV-2 Re

  2026-07-28

  Kerr et al. present an arrayed RNA interference screen that systematically identifies host vesicular transport factors crucial for SARS-CoV-2 release, particularly implicating Rab11a-mediated cargo delivery. Their findings clarify previously underexplored viral egress mechanisms and highlight CDK9 inhibition as a potential strategy for host-targeted antivirals.

• Ibuprofen Toxicology and Biodegradation: Environmental Persp

  2026-07-28

  Janet Jan-Roblero and Juan A. Cruz-Maya's 2023 review critically examines the toxicological impact and environmental persistence of ibuprofen as an emerging contaminant. The paper highlights the gap between high global consumption and limited biodegradation strategies, underlining the need for improved removal technologies and further research on bacterial degradation.

• SMYD2 Inhibition Mitigates Renal Fibrosis in Cisplatin-Induc

  2026-07-27

  This study demonstrates that pharmacological inhibition of SMYD2, particularly with AZ505, reduces renal fibrosis and inflammation in cisplatin-induced chronic kidney disease (CKD) models. The findings highlight SMYD2 as a promising epigenetic target in renal pathology, providing new mechanistic insights and supporting the use of selective SMYD2 inhibitors in translational fibrosis research.

• Tamsulosin (C6445): Mechanistic Insights for Precision POUR

  2026-07-27

  Explore how Tamsulosin, a selective α₁A-adrenergic receptor antagonist, redefines precision prophylaxis for postoperative urinary retention (POUR) and ureteral stone expulsion. This article provides a mechanistic and translational perspective, integrating meta-analytic evidence with advanced protocol guidance for research and clinical assay design.

8419 records 7/562 page Previous Next First page 上5页 678910 下5页 Last page